Clark RM, et al. - In this review, researchers analyzed the literature to determine rates, risk factors, and predictors of 30-day readmission in patients with advanced-stage ovarian epithelial ovarian cancer. They analyzed appropriate studies from MEDLINE (PubMed) out of all those published between January 1, 2008-January 01, 2018. For ovarian cancer patients undergoing primary treatment, the estimated 30-day readmission rates ranged from 2.5–19.3%. They also observed that neoadjuvant chemotherapy and interval cytoreductive surgery vs primary debulking surgery was related to lower readmission rates. The presence of other medical comorbidities, re-operation, and major complications occurring after initial hospital discharge were identified as predictors of readmission.